Diligence memo · auto-generated · as of July 2, 2026

VeraDermics, Inc

VeraDermics, Inc has raised $239M over 5 rounds; too few niche peers to rank its valuation yet.

SourceRaising on rhythm with a 2.0× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

VeraDermics, Inc operates in Other Health Care, based in New Haven.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

VeraDermics, Inc has raised $239M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $135M on 2025-10-14.

Most recent recorded round closed around 2025-10-14.

Valuation (modeled)modeled

Provath models VeraDermics, Inc at approximately $1.0B (range $719M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 9 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 2.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 99% of Other Health Care peers (5377 compared).

Modeled value ranks above 97% of those peers.

Closest niche peers: Wugen, Inc., HeartFlow Holding, Inc., Enable Injections, Inc.

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.